The estimated Net Worth of Scott T. Rottinghaus is at least $457 Tisíc dollars as of 11 July 2024. Scott Rottinghaus owns over 11,945 units of Enanta Pharmaceuticals Inc stock worth over $261,473 and over the last 2 years Scott sold ENTA stock worth over $195,904.
Scott has made over 2 trades of the Enanta Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Scott sold 11,945 units of ENTA stock worth $190,762 on 11 July 2024.
The largest trade Scott's ever made was selling 11,945 units of Enanta Pharmaceuticals Inc stock on 11 July 2024 worth over $190,762. On average, Scott trades about 1,783 units every 31 days since 2022. As of 11 July 2024 Scott still owns at least 21,717 units of Enanta Pharmaceuticals Inc stock.
You can see the complete history of Scott Rottinghaus stock trades at the bottom of the page.
Scott's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb... a Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include: